StreetInsider.com News Articles

Livanova (LIVN) PT Raised to $90 at Piper Sandler

Wed, 02 Sep 2026 09:18:23 -0400

(Updated - September 2, 2026 9:18 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Livanova (NASDAQ: LIVN) to $90.00 (from $87.00) while maintaining a Overweight rating.

The analyst commented: "CP Modeling Exercise Points To Healthy Growth Outlook; Following concerns over the U.S. cardiopulmonary (CP) Q2 result and general durability of the CP franchise, we sharpened our pencils to better understand the opportunity in front of LIVN over the next several years. Our note takes a closer look at the key components and future growth drivers of the CP franchise—some of which feel either misunderstood (e.g. Essenz HLM opportunity)

Livanova (LIVN) PT Raised to $90 at Piper Sandler

Wed, 02 Sep 2026 09:18:23 -0400

(Updated - September 2, 2026 9:18 AM EDT)

Piper Sandler analyst Adam Maeder raised the price target on Livanova (NASDAQ: LIVN) to $90.00 (from $87.00) while maintaining a Overweight rating.

Form 4 LivaNova PLC For: Aug 11 Filed by: Tezel Ahmet

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920637.html

Form 4 LivaNova PLC For: Aug 11 Filed by: Tezel Ahmet

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920637.html

Form 144 LivaNova PLC Filed by: Tezel Ahmet

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905840.html

Form 144 LivaNova PLC Filed by: Tezel Ahmet

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905840.html

Form SCHEDULE 13G LivaNova PLC Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881223.html

Form SCHEDULE 13G LivaNova PLC Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881223.html

Form IRANNOTICE LivaNova PLC

Wed, 05 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26873039.html

Form IRANNOTICE LivaNova PLC

Wed, 05 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26873039.html

Form 10-Q LivaNova PLC For: Jun 30

Wed, 05 Aug 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26873028.html

Form 10-Q LivaNova PLC For: Jun 30

Wed, 05 Aug 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26873028.html

Livanova (LIVN) PT Raised to $85 at Stifel

Wed, 05 Aug 2026 13:44:52 -0400

Stifel analyst Rick Wise raised the price target on Livanova (NASDAQ: LIVN) to $85.00 (from $80.00) while maintaining a Buy rating.

Livanova (LIVN) PT Raised to $93 at Needham

Wed, 05 Aug 2026 13:07:44 -0400

(Updated - August 5, 2026 1:07 PM EDT)

Needham analyst Mike Matson raised the price target on Livanova (NASDAQ: LIVN) to $93.00 (from $81.00) while maintaining a Buy rating.

The analyst commented: "LIVN's 2Q26 revenue and EPS beat consensus and LIVN raised its 2026 organic revenue and EPS guidance. Organic revenue growth slowed to 9.8% in 2Q26 from 11.1% in 1Q26. Both LIVN's Cardiopulmonary and Neuromodulation businesses beat consensus. Neuromodulation saw stronger growth while Cardiopulmonary saw slower growth. Gross margin was up 210 bps Y/Y due to tariff refunds (which added ~150 bps), mix, and currency and operating margin was up 130

Livanova (LIVN) PT Raised to $93 at Needham

Wed, 05 Aug 2026 13:07:44 -0400

(Updated - August 5, 2026 1:07 PM EDT)

Needham analyst Mike Matson raised the price target on Livanova (NASDAQ: LIVN) to $93.00 (from $81.00) while maintaining a Buy rating.

Form 3 LivaNova PLC For: Aug 01 Filed by: Folli Stefano

Wed, 05 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26869508.html

Form 3 LivaNova PLC For: Aug 01 Filed by: Folli Stefano

Wed, 05 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26869508.html

Form 8-K LivaNova PLC For: Aug 05

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869507.html

Form 8-K LivaNova PLC For: Aug 05

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869507.html

LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance

Wed, 05 Aug 2026 06:04:07 -0400

LivaNova plc (NASDAQ: LIVN) reported Q2 EPS of $1.26, $0.17 better than the analyst estimate of $1.09. Revenue for the quarter came in at $390.6 million versus the consensus estimate of $380.57 million.

GUIDANCE:

LivaNova plc sees FY2026 EPS of $4.30-$4.40, versus the consensus of $4.25.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.

LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance

Wed, 05 Aug 2026 06:04:07 -0400

GUIDANCE:

LivaNova plc sees FY2026 EPS of $4.30-$4.40, versus the consensus of $4.25.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

GLOUCESTER, England--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance.

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared